| __timestamp | Exelixis, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 189101000 | 45967000 |
| Thursday, January 1, 2015 | 96351000 | 114737000 |
| Friday, January 1, 2016 | 95967000 | 183204000 |
| Sunday, January 1, 2017 | 112171000 | 231644000 |
| Monday, January 1, 2018 | 182257000 | 293998000 |
| Tuesday, January 1, 2019 | 336964000 | 357355000 |
| Wednesday, January 1, 2020 | 547851000 | 412084000 |
| Friday, January 1, 2021 | 693716000 | 497153000 |
| Saturday, January 1, 2022 | 891813000 | 705789000 |
| Sunday, January 1, 2023 | 1044071000 | 648449000 |
| Monday, January 1, 2024 | 910408000 |
In pursuit of knowledge
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Exelixis, Inc. and Ultragenyx Pharmaceutical Inc. have demonstrated significant investment in R&D, reflecting their dedication to advancing medical science.
From 2014 to 2023, Exelixis, Inc. increased its R&D expenses by over 450%, showcasing a robust growth trajectory. This upward trend highlights the company's strategic focus on expanding its research capabilities and pipeline.
Ultragenyx Pharmaceutical Inc. also exhibited a strong commitment to R&D, with a 1,300% increase in spending from 2014 to 2022. Despite a slight dip in 2023, the company's overall trend underscores its persistent drive to innovate.
These trends underscore the dynamic nature of the biotech industry, where sustained R&D investment is key to long-term success.
Who Prioritizes Innovation? R&D Spending Compared for Vertex Pharmaceuticals Incorporated and Exelixis, Inc.
Research and Development Expenses Breakdown: Zoetis Inc. vs Exelixis, Inc.
Research and Development: Comparing Key Metrics for GSK plc and Ultragenyx Pharmaceutical Inc.
R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
R&D Insights: How Exelixis, Inc. and CymaBay Therapeutics, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ionis Pharmaceuticals, Inc.
R&D Insights: How Exelixis, Inc. and Amicus Therapeutics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Exelixis, Inc. and ACADIA Pharmaceuticals Inc.
R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs MorphoSys AG
Who Prioritizes Innovation? R&D Spending Compared for Ultragenyx Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Ultragenyx Pharmaceutical Inc. and MannKind Corporation
R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs Viridian Therapeutics, Inc.